HSA Approves "Comirnaty" as the New Brand Name for Pfizer-BioNTech's COVID-19 Vaccine
The Health Sciences Authority (HSA) has on 14 September 2021 approved the application by Pfizer to introduce the branded version of its COVID-19 vaccine, Comirnaty, under the Pandemic Special Access Route. The Comirnaty COVID-19 Vaccine is manufactured according to the same processes as the Pfizer-BioNTech COVID-19 Vaccine, with the same efficacy and safety aspects. The only difference is the labelled name.
2 Singapore had received several batches of Comirnaty and the vaccines have been used in our national vaccination programme.
HEALTH SCIENCES AUTHORITY
14 SEPTEMBER 2021
Download pdf version here 638 KB